{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"50.150","rs_stock_flag":false,"fiscal_year_end":"2025年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"112,712,832","primaryexch":"香港交易所","ric":"6887.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BV6FYB4","am":"17.02","iv":"","ew_strike":"","as":"49.400","geographic_focus":null,"incorpin":"中華人民共和國","etp_baseCur":null,"ew_amt_os":"","bd":"48.900","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-09-28 00:06:03.0","lo52":"47.440","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"張英俊","underlying_ric":"6887.HK","hi52":"62.300","issuer_name":"廣東東陽光藥業股份有限公司 - H股","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:00","aum_date":"","lo":"48.900","mkt_cap":"5.54","f_aum_hkd":null,"ew_sub_per_to":"","ls":"49.160","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.890","aum":"","issued_shares_class_B":null,"vo":"345.10","secondary_listing_flag":false,"listing_date":"2025年8月7日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"廣東東陽光藥業股份有限公司 - H股","nm_s":"東陽光藥","sym":"6887","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.020","strike_price":"","summary":"廣東東陽光藥業股份有限公司是一家主要從事藥物的研發、生產和商業化的中國公司。該公司專注於創新藥，亦涉及改良型新藥、仿製藥和生物類似藥。該公司的抗感染產品包括可威（磷酸奧司他韋），用於治療流行性感冒（特別是甲型及乙型流行性感冒病毒），東衛恩（磷酸依米他韋），用於治療丙型肝炎，及主要用於治療敏感細菌引起的感染的仿製藥，即克拉霉素、左氧氟沙星及鹽酸莫西沙星。該公司的慢病治療藥物主要專注於治療糖尿病、高尿酸血症、高血壓及胃酸相關疾病，包括胰島素產品及仿製藥。該公司還關注腫瘤治療領域。","op":"50.150","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"藥品","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"中國廣東省<br/>東莞市<br/>松山湖園區<br/>工業北路1號","pc":"-1.78","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"50.050","isin":"CNE1000070M8","moneyness":""}},"qid":"1759074341039"}
